International Medical ManagerNovo Nordisk A/S, Søborg, DenmarkSøborg, Hovedstaden, Denmark
OC 59.1 - Concizumab prophylaxis in patients with haemophilia A or B without inhibitors: Efficacy and safety results from the primary analysis of the phase 3 explorer8 study
Tuesday, June 27, 202314:45 – 15:00 ET
OC 59.4 - Health-related quality of life, treatment burden and patient preference in patients with haemophilia A/B without inhibitors on concizumab prophylaxis: results from the phase 3 explorer8 study
Tuesday, June 27, 202315:30 – 15:45 ET
